Twist Bioscience Ipo Prospectus

Twist bioscience ipo prospectus

Twist bioscience ipo prospectus

As filed with the Securities and Exchange Commission on May 6, 2019

Registration

No. 333-                

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.

20549

 

 

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

 

 

TWIST BIOSCIENCE CORPORATION

(Exact name of Registrant as specified in its charter)

 

 

 

Delaware

 

2836

 

(State or other jurisdiction of

incorporation or organization)

 

(Primary Standard Industrial

Classification Code Number)

 

(I.R.S.

Twist Bioscience: Writing the Future with Synthetic DNA

Employer

Identification Number)

455 Mission Bay Boulevard South, Suite 545

San Francisco, CA 94158

(Address, including zip code, and telephone number, including area code, of Registrant’s principal executive offices)

 

 

Emily M.

Leproust

President and Chief Executive Officer

Twist Bioscience Corporation

455 Mission Bay Boulevard South, Suite 545

San Francisco, CA 94158

(Name, address including zip code, and telephone number including area code, of agent for service)

 

 

COPIES TO:

 

John V.

Bautista, Esq.

Andrew D.

Twist bioscience ipo prospectus

Thorpe, Esq.

Peter M. Lamb, Esq.

Melissa V. Frayer, Esq.

Orrick, Herrington & Sutcliffe LLP

1000 Marsh Road

Menlo Park, CA 94025

 

Mark Daniels, Esq.

General Counsel

Twist Bioscience Corporation

455 Mission Bay Boulevard

Suite 545

San Francisco, CA 94158

 

Brian J.

Twist bioscience ipo prospectus

Cuneo, Esq.

B. Shayne Kennedy, Esq.

Latham & Watkins LLP

140 Scott Drive

Menlo Park, CA 94025

 

 

Approximate date of commencement of proposed sale to the public:

As soon as practicable after this Registration Statement becomes effective.

 

 

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box.  

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a

non-accelerated

filer, a smaller reporting company, or an emerging growth company.

Twist Bioscience Stock Offered in IPO

See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule

12b-2

of the Securities Exchange Act of 1934:

 

Large accelerated filer

 

  

Accelerated filer

 

Non-accelerated filer

 

  

Smaller reporting company

 

 

  

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided to Section 7(a)(2)(B) of the Securities Act. 

 

 

CALCULATION OF REGISTRATION FEE

 

 

Title of each class of

securities to be registered

 

Amount

to be

registered(1)

 

Proposed

maximum

offering price

per unit(2)

 

Proposed

maximum

aggregate

offering price(2)

 

Amount of
registration fee

Common Stock, par value $0.00001 per share

 

3,450,000

 

$24.92

 

$85,974,000

 

$10,421

 

 

(1)

 

Includes 450,000 shares of Common Stock issuable upon exercise of the Underwriters’ option to purchase additional shares.

See “Underwriting.”

(2)

 

Estimated solely for the purpose of computing the amount of the registration fee pursuant to Rule 457(c) under the Securities Act of 1933, as amended, and is based on the average of the high and low sales prices of the registrant’s common stock as reported on the Nasdaq Global Select Market on May 3, 2019.

Twist bioscience ipo prospectus

 

 

The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until the Registration Statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine.

 

 

 

Twist bioscience ipo prospectus